Affymax (OTCMKTS:AFFY) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Posted by on Jan 2nd, 2026

Affymax Inc. (OTCMKTS:AFFY – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.0008. Affymax shares last traded at $0.0008, with a volume of 2,550 shares changing hands.

Affymax Stock Down 42.9%

Affymax Company Profile

(Get Free Report)

Affymax, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare and underserved diseases. The company leverages its proprietary TransCon® drug delivery platform to create prodrugs that offer sustained, predictable release of active pharmaceutical ingredients. Affymax’s research efforts concentrate on endocrinology and nephrology indications, seeking to address conditions that currently have limited treatment options.

Among its lead product candidates, Affymax is advancing TransCon® PTH for the treatment of hypoparathyroidism and TransCon® Growth Hormone (TransCon® GH) for pediatric growth hormone deficiency.

Featured Articles

Receive News & Ratings for Affymax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax and related companies with MarketBeat.com's FREE daily email newsletter.